Gene therapy using lentiviral vectors has already led to major clinical successes when applied ex vivo - meaning that patients' stem cells are genetically modified in the lab and reinfused after ...

The YOLT-203 in-vivo gene editing therapy was developed to treat patients living with primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine ...

Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case Sep. 25, 2024 4:40 PM ET Intellia Therapeutics, Inc. (NTLA) Stock REGN , NTLA 29 Comments 1 Like Edmund Ingham ...

All gene therapy approaches currently used in the clinic for genetic diseases are ex vivo, meaning we have to take the patient’s cells out of their body to modify them. ... For in vivo gene therapy to ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact at the same time as it searches for a ...

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting Editas Medicine, Inc. Tue, May 13, 2025, 7: ...

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Precision BioSciences, Inc ...